STANDBY EQUITY PURCHASE AGREEMENTStandby Equity Purchase Agreement • December 18th, 2024 • InMed Pharmaceuticals Inc. • Pharmaceutical preparations
THIS STANDBY EQUITY PURCHASE AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of December 13, 2024, is made by and between YA II PN, LTD., a Cayman Islands exempt limited company (the “Investor”), and INMED PHARMACEUTICALS INC., a company organized under the laws of British Columbia, Canada (the “Company”).
InMed Enters Into Standby Equity Purchase AgreementStandby Equity Purchase Agreement • December 18th, 2024 • InMed Pharmaceuticals Inc. • Pharmaceutical preparations
Vancouver, British Columbia – December 17, 2024. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase Agreement (the “SEPA”) with YA II PN, LTD (the “Investor”), an investment fund managed by Yorkville Advisors Global LP, a global investment manager, on December 13, 2024 (the “Effective Date”) to sell up to $10 million in the aggregate of the Company’s common shares, no value (the “Common Shares”), at any time during the 36-month period following the Effective Date of the SEPA, subject to the effectiveness of a registration statement with the Securities and Exchange Commission and other conditions set forth in the SEPA.
